CryoPort (NASDAQ:CYRX) Posts Earnings Results, Misses Expectations By $0.01 EPS

CryoPort (NASDAQ:CYRX) posted its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01), Zacks reports. The firm had revenue of $48.97 million for the quarter, compared to analysts’ expectations of $48.18 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.13%.

Here are the key takeaways from CryoPort’s conference call:

• Revenue reached $49 million in the second quarter, with Life Sciences Services revenue up 15% year over year, commercial cell and gene therapy support revenue up 9%, and clinical-trial support revenue up 12%.
• Cryoport achieved positive adjusted EBITDA of $400,000, a $1.3 million year-over-year improvement, and generated approximately $5 million of operating cash flow in the first half, supporting management’s path toward sustainable profitability.
• The company’s pipeline remains broad, with 779 clinical trials supported globally, 22 commercial cell and gene therapies, and expectations for 11 potential BLA/MAA filings, five new therapy approvals, and one label or geographic expansion during the remainder of 2026.
• Cryoport reaffirmed its 2026 continuing-operations revenue guidance of $192 million to $196 million rather than raising it, citing geopolitical and macroeconomic uncertainty despite strong underlying demand.
• New growth initiatives—including IntegriCell cryopreservation services, the Fusion 811 freezer, China-based manufacturing, and new supply-chain facilities in Paris and Santa Ana—are expected to expand future capacity, although IntegriCell is not expected to contribute significantly to 2026 revenue.

CryoPort Price Performance

Shares of NASDAQ:CYRX traded up $0.41 during midday trading on Friday, reaching $15.12. The company had a trading volume of 1,069,240 shares, compared to its average volume of 609,580. The stock has a market capitalization of $762.05 million, a P/E ratio of -16.80 and a beta of 1.89. The stock’s fifty day moving average price is $15.49 and its 200-day moving average price is $11.92. CryoPort has a one year low of $7.51 and a one year high of $16.89.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

Insider Buying and Selling at CryoPort

In other CryoPort news, CFO Robert Stefanovich sold 169,427 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the completion of the transaction, the chief financial officer directly owned 109,850 shares of the company’s stock, valued at $1,787,259.50. This trade represents a 60.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Edward J. Zecchini sold 33,600 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $14.47, for a total transaction of $486,192.00. Following the completion of the sale, the insider directly owned 109,719 shares of the company’s stock, valued at $1,587,633.93. The trade was a 23.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 227,641 shares of company stock worth $3,622,515 in the last ninety days. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its position in shares of CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares in the last quarter. Quadrature Capital Ltd bought a new position in CryoPort during the fourth quarter worth $97,000. Corient Private Wealth LLC bought a new position in CryoPort during the fourth quarter worth $113,000. BNP Paribas Financial Markets boosted its holdings in CryoPort by 55.2% in the third quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock worth $113,000 after purchasing an additional 4,225 shares during the period. Finally, Creative Planning acquired a new position in CryoPort in the second quarter worth $96,000. Institutional investors own 92.90% of the company’s stock.

Wall Street Analysts Forecast Growth

CYRX has been the topic of several analyst reports. KeyCorp lifted their price target on shares of CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen upgraded CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Guggenheim lifted their target price on CryoPort from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday. Needham & Company LLC boosted their price target on CryoPort from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Jefferies Financial Group set a $13.50 price target on CryoPort in a research note on Monday, June 8th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.